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potential use of surrogate end points in the development of
new treatments in PBC [3–5]. Our observations alongside those
of Joshita et al., further substantiate the role stratiﬁcation could
play, not just in clinical practice but also in clinical trial design.
Hence, future therapeutic trials in PBC should consciously con-
sider inclusion criteria beyond classic response criteria, and such
stratiﬁers may include additional tools such as liver elastography
and APRI-r1. Finally, as is evident from our studies, in the pursuit
of optimal management for a rare disease such as PBC, methodo-
logically robust, internationally representative, numerically well-
powered cohorts are essential in order to allow investigators to
make clear replicated observations about disease nature, course
and intervention.
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We read with interest the letter by Joshita and colleagues
regarding our original article [1]. In taking the time to present
their important Japanese data [2], the authors provide further
independent validation of the AST/platelet ratio (APRI) in the risk
stratiﬁcation of patients with primary biliary cirrhosis (PBC). As
the authors surmise, the demography of our cohorts was varied
but was not representative of all populations globally, and the
robustness of any observation – even if simple and low cost as
in this case – is in validation more so than in discovery.
PBC is not a benign, homogeneous autoimmune liver disease;
and although present disease nomenclature needs improvement
the current sole therapy – ursodeoxycholic acid (UDCA) – still
leaves a substantial cohort of individuals at risk from life-
threatening progressive disease and impaired quality of life. Risk
stratiﬁcation is therefore of value to identify individuals with
PBC who will beneﬁt from new treatments and as illustrated
herein, APRI at baseline or reapplied 1-year following therapy
(APRI-r1) represents an additive tool in identifying those patients
at risk of adverse clinical outcomewith high accuracy. Joshita et al
also report good correlation between APRI and disease stage; [2]
however, it is apparent in both studies that a signiﬁcant propor-
tion of patients have an APRI >0.54 despite histological evidence
of early stage (I-II) disease. Moreover, in our study we were able
to show that in those without objective evidence of cirrhosis
APRI retains independent predictive value, thus supporting
APRI/APRI-r1 as a prognostic, clinically meaningful utility beyond
application as a surrogate for liver ﬁbrosis.
The ability to reliably predict outcome in patients with PBC is
beneﬁcial for patient counselling, timing of diagnostic proce-
dures, and therapeutic intervention. In this regard, prospective
evaluation of APRI-r1 in terms of additive value to existing UDCA
response criteria is of clear importance; particularly given theJournal of Hepatology 2014 vol. 61 j 1438–1452 1445
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Low free T3 levels are related to early mortality
in patients with decompensated cirrhosis and acute-on
chronic liver failure
To the Editor:
We read with interest the article by Maiwall et al. in which serum
ferritin along with hepatic encephalopathy, leukocyte count,
acute-on-chronic liver failure (ACLF) grades and CTP score predict
early mortality in patients with decompensated cirrhosis (DC)
[1]. ACLF has recently been recognized as a speciﬁc clinical form
of liver failure with short term mortality [2,3]. Thyroid test
abnormalities in ACLF and their association with survival have
not been determined so far.
The plasma thyroid hormone proﬁle in patients with cirrhosis
resembles the low T3 or ‘‘sick euthyroid’’ syndrome, common in
many sick patients and normal subjects with caloric deprivation
[4,5]. Thus, a low T3 state in cirrhosis may reﬂect impairment of
hepatic uptake and conversion of T4 to T3 due to diminished
hepatocellular function or to reduced caloric intake. It may be
considered as an adaptive hypothyroid state, which is important
for preserving body protein stores [6]. We aimed to better
understand the thyroid test abnormalities in patients with (DC)
and ACLF compared to those without ACLF.
128 patients (91 [71.1%] males, median age of 61 [interquar-
tile range 53–69] years) with DC were followed for a median of
91 (44–110) days. ACLF was diagnosed in 65 (50.8%) patients
according to the CLIFF consortium criteria [2]. No patient had
signs or symptoms of thyroid disease. Levels of free T3 (FT3)
and free T4 (FT4) correlated inversely with the severity of liver
disease as expressed by the MELD-Na score (r = 0.482 and
0.346, respectively, p <0.001). On the contrary, there was no
correlation of the thyroid-stimulating hormone (TSH) with the
MELD-Na score.
Patients with ACLF compared to those without had signiﬁ-
cantly lower FT3 (1.54 [1.18–1.88] vs. 2.00 [1.55–2.46],
p <0.001) and FT4 levels (1.00 [0.83–1.19] vs. 1.14 [1.00–1.24],
respectively, [p = 0.005]). TSH did not differ between the two
groups. 42 (65%) and 18 (29%) patients had low FT3 levels in
the ACLF and non-ACLF group, respectively (p <0.001). Patients
with low FT3 compared to those with normal FT3 had signiﬁ-
cantly higher sequential-organ-failure-assessment (SOFA) (six
[5–8] vs. ﬁve [4–7.25], p = 0.023). Patients with low FT3 had a
worse outcome as it is shown by the Kaplan Mayer survival curve
(log rank p <0.042) (Fig. 1). On the contrary, only nine patients,
seven in the ACLF and two in the non-ACLF group, had low FT4
levels (p = 0.09). Low FT4 levels were not related to outcome.
It is not the ﬁrst time that the sick euthyroid syndrome has
been related to the prognosis of liver cirrhosis. In the past, low
levels of the T4 variant in the sick euthyroid syndrome were
demonstrated to be a good predictor of decreased survival in liver
cirrhosis and T4 levels were inversely correlated with the CTP
score [6]. In addition, low FT3 levels were considered as indicators
of poor prognosis in cirrhotics with non alcoholic liver disease
[5]. However, the prognostic signiﬁcance of low T3 levels in
the sick euthyroid syndrome have not been evaluated so far in
the ACLF setting.
In conclusion, free T3 levels are inversely correlated with the
severity of liver disease and are signiﬁcantly lower in patients
with decompensated cirrhosis who developed ACLF. Sick
euthyroid syndrome with low FT3 levels was related to early
mortality in patients with ACLF.
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Fig. 1. Probability of survival in patients with low compared to normal FT3 in
ACLF group.
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